Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes

• Status: Recruiting
• Trial end date: 2026-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Obese women with history of gestational diabetes are in great danger to develop type 2 diabetes (T2D) within 5-10 years after delivery. Aim of the study is to investigate if 12 months' liraglutide treatment could decrease the risk of T2D in obese women who have had gestational diabetes. The women are randomized either to liraglutide (Victoza ® 1.8 mg) or placebo group, once daily. Same laboratory tests are taken and instructions given at baseline 6 month and one year. After one year visits once a year until 5 years with same laboratory tests and measurements are taken.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Turku University Hospital
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• history of gestational diabetes with treatment with metformin and/or insulin

• delivery 6 to 18 months before screening

• BMI ≥30 kg/m2

• use of contraceptives (IU-device or oral contraceptive)

Exclusion Criteria:

• lactation

• pregnancy

• type 1 or type 2 diabetes

• use of antidepressives, statins or anti-hyperglycemic therapies

• severe hepatic insufficiency

• end stage renal disease

• history of pancreatitis